ORPHA:558
Marfan syndrome
Also known as: MFS
Publications
28,422
Trials
27
Interventional, condition-specific
Researchers
1,180
Distinct authors in sample
Gene link
FBN1
Definitive
Readiness
6/6
Stages with a signal
Clinical definition (Orphanet)
Marfan syndrome is a systemic disease of connective tissue characterized by a variable combination of cardiovascular, musculo-skeletal, ophthalmic and pulmonary manifestations.
How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007947
- MeSH:D008382
- OMIM:154700
- UMLS:C0024796
- NCIT:C34807
Additional Mondo synonyms (4)
MFS1 · Marfan syndrome type 1 · Marfan syndrome, type 1 · Marfan's syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
6/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — FBN1
- LiteraturePresent
28,422 matched papers (15,334 in last 10 years) Source
- Phenotype characterisedPresent
181 HPO annotations (e.g. Mitral regurgitation; Emphysema; Tricuspid regurgitation) Source
- Animal modelPresent
10 genotype models (Mus musculus) Source
- Orphan designationPresent
1 FDA · 1 EMA designations (1 FDA orphan-indication approval) — e.g. losartan Source
- Interventional trialPresent
27 matched on ClinicalTrials.gov (4 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (FBN1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
181
Associated phenotypes · MONDO:0007947
- Mitral regurgitation
- Emphysema
- Tricuspid regurgitation
- Dolichocephaly
- Megalocornea
Showing 5 of 181 — open Monarch for the full list.
Animal models (Monarch / Alliance)
10
Model associations linked to this Mondo ID
- Fbn1tm2Rmz/Fbn1tm2Rmz [background:] involves: 129S1/Sv * 129X1/SvJ·MGI:3619460·Mus musculus
- Fbn1tm1Rmz/Fbn1tm1Rmz [background:] involves: 129S4/SvJae * C57BL/6J·MGI:3619415·Mus musculus
- Fbn1tm1Hcd/Fbn1+ [background:] involves: 129S1/Sv * 129X1/SvJ * C57BL/6J·MGI:3690327·Mus musculus
- Fbn1Tsk/Fbn1+ [background:] B10.D2/(58N)Sn·MGI:3604814·Mus musculus
- Fbn1Tsk/Fbn1+ [background:] B6.Cg-Fbn1Tsk·MGI:3619520·Mus musculus
- Fbn1tm1Lper/Fbn1+ [background:] involves: 129/Sv * C57BL/6 * CD-1·MGI:4880671·Mus musculus
- Fbn1tm3Rmz/Fbn1tm3Rmz [background:] Not Specified·MGI:3652414·Mus musculus
- Mus81tm1Esse/Mus81tm1Esse [background:] involves: 129P2/OlaHsd * C57BL/6·MGI:3794044·Mus musculus
- Fbn1tm1Lper/Fbn1+ [background:] involves: 129/Sv * CD-1·MGI:4880670·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
2
Designations · 1 with FDA orphan-indication approval
- FDA losartanMarfan Syndrome · 2011-12-12 · Not FDA Approved for Orphan Indication
- EMA allopurinolTreatment of Marfan syndrome · 25/03/2025 · PositiveEMA designation
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
7
Drugs / clinical candidates · MONDO_0007947
- ALISKIREN·phase 3
- ATENOLOL·phase 3
- LOSARTAN·phase 3
- NEBIVOLOL·phase 3
- PERINDOPRIL·phase 3
- DOXYCYCLINE·phase 2
- IRBESARTAN·phase 2
CTD chemicals (MyDisease.info)
4 associated chemicals · 117 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Atenolol · therapeutic
- Doxycycline · therapeutic
- Losartan · therapeutic
- Thiobarbituric Acid Reactive Substances · marker/mechanism
Pathways: Arginine biosynthesis; Arginine and proline metabolism; Tryptophan metabolism; Glyoxylate and dicarboxylate metabolism; Metabolic pathways; Carbon metabolism; Endocrine resistance; MAPK signaling pathway
Literature
Is anyone studying this?
28,422
28,422 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
28,422 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
15,334 in the last 10 years · low confidence
Phrase hits: 22,294 · MeSH hits: 595
Who's working on it?
1,180
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang Y6 papers · 2026
From the Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University.
Papers in Europe PMC - 02Humphrey JD5 papers · 2026
Department of Biomedical Engineering, Yale University, New Haven, CT (D.W., B.V.R., C.C., D.S.L., Y.K., N.E., J.D.H.).
Papers in Europe PMC - 03Chen X4 papers · 2026
Department of Mechanical Engineering, Graduate School of Sciences and Technology for Innovation, Yamaguchi University, Yamaguchi, Yamaguchi, Japan.
Papers in Europe PMC - 04He H4 papers · 2026
Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan ,430022, China.
Papers in Europe PMC - 05Abdul Nabi H3 papers · 2026
Department of Cardiovascular Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
Papers in Europe PMC - 06
- 07Badawi AH3 papers · 2026
Vitreoretinal Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
Papers in Europe PMC - 08Cavinato C3 papers · 2026
Department of Biomedical Engineering, Yale University, New Haven, CT (D.W., B.V.R., C.C., D.S.L., Y.K., N.E., J.D.H.).
Papers in Europe PMC - 09Chen Z3 papers · 2026
From the Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University.
Papers in Europe PMC - 10Coselli JS3 papers · 2026
Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex. Electronic address: jcoselli@bcm.edu.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
27
interventional trials for this specific condition
27 interventional trials matched this specific condition name; 4 currently recruiting in our sample.
Data as of 11 September 2026 · last trial check 28 July 2026
27 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 95.7th percentile).
low confidence · 95.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
27 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05809323·RECRUITING·Marfan Syndrome Moderate Exercise Trial II
Not reviewed·Conditions: Marfan Syndrome·Matched via name + MeSH
- NCT07495267·NOT YET RECRUITING·Nutritional Ketosis Marfan
Not reviewed·Conditions: Marfan Syndrome · Aortic Dissection·Matched via name + MeSH
- NCT02050113·RECRUITING·Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices
Not reviewed·Conditions: Complex Aortic Aneurysms · Thoracoabdominal Aneurysms · Pararenal Aneurysms · Juxtarenal Aneurysms·Matched via name + MeSH
- NCT05838235·RECRUITING·Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Marfan Syndrome
Not reviewed·Conditions: Marfan Syndrome·Matched via name + MeSH
Observational and natural-history studies
35 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05702476·RECRUITING·Marfan Syndrome (MFS) and Facial Dysmorphism: Non-invasive 3D Assessment
Not reviewed·Conditions: Rare Diseases · Marfan Syndrome·Matched via name + MeSH
- NCT07419386·NOT YET RECRUITING·Clinical and Psychosocial Factors Associated With Physical Activity Level in Adults With Marfan Syndrome
Not reviewed·Conditions: Marfan Syndrome·Matched via name + MeSH
- NCT04194619·RECRUITING·Pregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 Study
Not reviewed·Conditions: Vascular Anomaly · Osler Rendu Disease · Marfan Syndrome or Related · Lymphedema Primary·Matched via name + MeSH
- NCT04970459·RECRUITING·Biological Collection for Marfan and Related Syndromes
Not reviewed·Conditions: Marfan Syndrome·Matched via name + MeSH
- NCT06786754·ENROLLING BY INVITATION·Fibroblasts and Thoracic Aortic Aneurysms: in Vitro Characterization in With Marfan Syndrome and Genetic Aortic Diseases
Not reviewed·Conditions: Rare Diseases · Thoracic Aortic Aneurysm (TAA) · Marfan Syndrome·Matched via name + MeSH
- NCT07169669·NOT YET RECRUITING·Multicentre Longitudinal Study of Bone Mineralisation Characteristics in Marfan Syndrome and Ehlers-Danlos Syndrome
Not reviewed·Conditions: Marfan Syndrome · Ehlers-Danlos Syndrome (EDS) · Mineral Density·Matched via name + MeSH
- NCT07672210·RECRUITING·PregnAncy-Related Aortic DISsEction in China
Not reviewed·Conditions: Pregnancy Complication · Aortic Dissection · Marfan Syndrome · Loeys-Dietz Syndrome·Matched via name + MeSH
- NCT06546137·RECRUITING·National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry
Not reviewed·Conditions: Cardiomyopathy, Hypertrophic · Cardiomyopathy, Dilated · Cardiomyopathy Restrictive · Arrhythmogenic Right Ventricular Dysplasia·Matched via name + MeSH
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 81 · after dedupe 80 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 80 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (80)
- isrctn·ISRCTN12803806·No longer recruiting·Machine learning to predict outcomes of type B aortic dissection patients following thoracic endovascular aortic repair
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN77727306·No longer recruiting·Impact of poor nutrition on survival rates in patients with aortic dissection undergoing heart surgery
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12054536·Recruiting·MiTiGate trial: Is Botox more effective than lidocaine and treatment as usual in myalgia temporomandibular disorder (TMD)?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN56368396·No longer recruiting·Exploring the natural history of myopic maculopathy and optic neuropathy in high myopia: Zhongshan High Myopia Cohort
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN50468704·No longer recruiting·Visual performance of three myopia control spectacles for children in China
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN88966184·No longer recruiting·Personalized treatment of knee osteoarthritis with fat tissue containing stem cells
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15002246·No longer recruiting·The role of collagen genetic discrepancies in development of pelvic organ prolapse in women
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13738704·No longer recruiting·Patients for patients – qualified peer-counselling and self-management for patients with rare chronic diseases
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN76992326·Stopped·Prevention of stretch marks in pregnancy: a pilot trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16152290·No longer recruiting·Osteoarthritis project
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16418171·Stopped·EFFect Of exercise on insulin ResisTance
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN90224545·No longer recruiting·Joint hypermobility: effect of a strength training program on disability and function
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN90011794·No longer recruiting·The effects of irbesartan on aortic dilatation in Marfan's syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN03530985·No longer recruiting·Comparison of outcomes following aortic valve replacement with two different types of valve substitutes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN48334791·No longer recruiting·Immediate management of patients with ruptured aneurysm: open versus endovascular repair
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN95777824·No longer recruiting·Regenerative effects of erythropoietin in burn and scald injuries
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN01285948·No longer recruiting·Effect of a plate haptic design on intraocular lens rotational-and-axial stability and posterior capsule opacification: a randomised trial (acrismart versus acrilyc intraocular lenses)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN34532248·Stopped·Laparoscopic versus Open Ventral Hernia repair using a classical versus Collagen MESH (Surgisis Gold®): a European Multicenter Two Factorial Randomized Controlled Trial (LAPSIS Trial)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN82800078·No longer recruiting·The effects of angiotensin 2 blockade on arterial stiffness in patients with Marfan Syndrome: a comparison with beta blockade and placebo (BETA BLOCKER)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN28168217·No longer recruiting·The effects of angiotensin 2 blockade and long acting nitrates on arterial stiffness in patients with Marfan Syndrome. A placebo controlled study (NITRATES)
skipped — LLM skipped (--skip-llm)
- ctis·2024-515059-39-00·Authorised, ongoing·Evaluation of the Efficacy of Valsartan in Slowing Down Aortic Root Dilatation in Children and Young Adults with Marfan-type Heritable Thoracic Aortic Diseases – Valsar-TAD, a randomised, double-blind, placebo-controlled multicentre trial
skipped — LLM skipped (--skip-llm)
- ctis·2025-524711-36-00·Authorised·A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
skipped — LLM skipped (--skip-llm)
- ctis·2025-524449-28-00·Authorised·A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes
skipped — LLM skipped (--skip-llm)
- ctis·2025-523503-30-00·Authorised·A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults with Narcolepsy
skipped — LLM skipped (--skip-llm)
- ctis·2025-522723-98-00·Authorised·A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Marfan syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Marfan syndrome" OR "Marfan syndrome type 1" OR "Marfan syndrome, type 1" OR "Marfan's syndrome") OR (MESH:"Marfan Syndrome") OR ("FBN1" OR "FBN1 syndrome" OR "FBN1-related")MeSH descriptor terms unioned into the query: Marfan Syndrome
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Marfan syndrome" OR "Marfan syndrome type 1" OR "Marfan syndrome, type 1" OR "Marfan's syndrome"
Interventional trials matched via: both (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 27 interventional · 35 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: MFS; MFS1
Confidence reasoning
- Preferred label is short or not clearly distinctive
- 2 synonym(s) dropped by stoplist (may under-count)
- "Marfan syndrome type 1" also appears on ORPHA:284963
Ingested 2026-07-26T14:20:01.198Z
